<p>
<strong><u>Release Date</u></strong><br/>
November x, 2014<br/><br/>
<strong><u>Expiration Date</u></strong><br/>
November x, 2015<br/><br/>

<strong><u>Faculty</u></strong><br/>
Stephen Hunger, MD <br>
University of Colorado Denver <br>
Denver, Colorado, United States <br><br>

Rob Pieters, MD, PhD <br>
Princess Máxima Center for Pediatric Oncology <br>
Utrecht, the Netherlands <br><br>



<strong><u>Learning Objectives:</u></strong><br/>
After successful completion of  this educational activity, participants should be able to:
<ul class="bullets">
  <li>Identify best practices for implementing therapeutic drug monitoring and managing hypersensitivity to optimize the use of asparaginase therapy in patients with acute lymphoblastic leukemia (ALL)</li>
  <li>Employ recent advances regarding the utilization of asparaginase therapy in patients with ALL based on emerging clinical trial data and current treatment recommendations</li>
</ul>
<br/>

<strong><u>Provider</u></strong><br/>
This activity is provided by prIME Oncology.<br/><br/>

<strong><u>Support</u></strong><br/>
This educational activity is supported by grant from Jazz Pharmaceuticals.

<strong><u>Target Audience</u></strong><br/>
This educational activity is designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with acute lymphoblastic leukemia (ALL).<br/><br/>

<strong><u>Continuing Medical Education</u></strong><br/>
prIME Oncology is accredited by the  Accreditation Council for Continuing Medical Education (ACCME<sup>&reg;</sup>) to  provide continuing medical education for physicians.<br/><br/>
prIME Oncology designates  this enduring activity for a maximum of xx<em> AMA PRA Category 1 Credits<sup>&trade;</sup>.&nbsp;</em>Physicians  should claim only the credit commensurate with the extent of their  participation in the activity.<br/><br/>

<strong><u>Method of Participation</u></strong><br/>
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.<br><br>

Technical requirements may be found under the&nbsp;<a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms  of Use</a>.<br><br>

Links to the posttest are available on the video player pages.<br/><br/>

In order to receive credit, participants must successfully complete the online posttest with 80 % or higher.<br/><br/>

<strong><u>Disclosure of Relevant Financial Relationships</u></strong><br/>
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.<br/><br/>

<strong><u>Faculty Disclosures</u></strong><br/>
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:<br/><br/>

Dr Hunger has disclosed that he has received consulting fees from Jazz Pharmaceuticals and Sigma Tau Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation. <br><br>

Dr Pieters has disclosed that he has received consulting fees from Jazz Pharmaceuticals, EUSA Pharma, Medac Pharma, and Sigma Tau Pharmaceuticals, Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation. <br><br>

The employees of prIME Oncology have disclosed:</p>
<ul class="bullets">
  <li>Janice Galleshaw, MD (medical content reviewer/planner) - no relevant financial relationships</li>
  <li>Trudy Stoddert, ELS (editorial content reviewer) - no relevant financial relationships</li>
</ul>

<p><br/>
<strong><u>Disclosure Regarding Unlabeled Use</u></strong><br/>
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.<br/><br/>

<strong><u>Disclaimer</u></strong><br/>
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.<br/>
</p>